NFL Biosciences: CESTO II trial progressing on schedule
NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants...
Pharmaceutical
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5%...
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),...
Procaps Announces Key Changes to the Board of Directors
International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors MIAMI and BARRANQUILLA, Colombia, Jan. 19, 2023...
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, Jan. 19, 2023...
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
FDA sets PDUFA date of May 22, 2023SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:...
AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation...
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with...
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a...
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational...
Dyadic Announces Sale of Equity Interest in Alphazyme
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology...
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University...
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry...